General
Preferred name
BUDIPINE
Synonyms
Budipine hydrochloride ()
Budipino ()
P&D ID
PD073086
CAS
57982-78-2
Tags
available
drug
Drug indication
Parkinson disease
Migraine
Drug Status
experimental
approved
investigational
withdrawn
Max Phase
2.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Budipine is an anti-parkinson agent. Budipine also is a substrate of P-glycoprotein (P-gp), is mediated the uptake into the brain by P-gp. Budipine also is N-methyl-d-aspartate (NMDA) antagonist, and has indirect dopaminergic effects through an improved dopamine release, the inhibition of monoamine oxidase type B (MAO-B). Budipine can be used for the research of CNS disorders include Parkinson disease[1].
PRICE
38
DESCRIPTION
Budipine is a low affinity, N-methyl-D-aspartate receptor antagonist,is an antiparkinsonian agent.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
13
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
DrugMatrix
Ki Database
MedChem Express Bioactive Compound Library
ReFrame library
TargetMol Bioactive Compound Library
Withdrawn 2.0
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
31
Molecular Weight
293.21
Hydrogen Bond Acceptors
1
Hydrogen Bond Donors
0
Rotatable Bonds
2
Ring Count
3
Aromatic Ring Count
2
cLogP
4.87
TPSA
3.24
Fraction CSP3
0.43
Chiral centers
0.0
Largest ring
6.0
QED
0.76
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target
N-methyl-D-aspartate
GRIN1
iGluR
Indication
Parkinson's Disease
MOA
glutamate receptor antagonist
ATC
N04BX03
Toxicity type
cardiovascular
Pathway
Membrane Transporter/Ion Channel
Neuronal Signaling
Source data

